Deep learning‐assisted design of nanozyme for immune regulation

Inflammatory bowel disease (IBD), with rising global incidence and disease burden, is a multifactorial disorder characterized by chronic and relapsing gastrointestinal inflammation. Its pathogenesis involves immune dysregulation, reactive oxygen species bursts, and microbiota imbalance. Intestinal immune dysregulation drives IBD progression, making precise immune regulation essential for controlling inflammation and improving long‐term outcomes. Despite advances in clinical therapeutics such as corticosteroids and biologics, durable remission remains difficult due to limited targeting and side effects. Nanozymes have emerged as a promising treatment strategy for IBD owing to their structural stability, tunable catalytic performance, and capacity to regulate oxidative stress and inflammation. Deep learning (DL)‐assisted nanozyme engineering facilitates precise matching of catalytic activity and environmental responsiveness to the complex and dynamic inflammatory microenvironment of IBD, thereby enhancing immune regulation and therapeutic efficacy. In this review, we summarize recent advances in nanozyme‐based strategies for IBD, with an emphasis on DL‐assisted design and functional optimization. We discuss current challenges and future perspectives for nanozyme therapeutics, including biosafety evaluation and clinical translation toward precision management of IBD.